Frank V. Brozovich

Frank V. Brozovich

Auto-generated profile, based on publicly available information

Frank V. Brozovich

Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55902

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SYSamantha Yuen
Samantha Yuen
OOOzgur Ogut
Ozgur Ogut
FBFrank V. Brozovich
Frank V. Brozovich
Smooth muscle relaxation in response to NO signaling is due, in part, to a Ca2+-independent activation of myosin light chain (MLC) phosphatase by protein kinase G Iα (PKGIα). MLC phosphatase is a trimeric complex of a 20-kDa subunit, a 38-kDa catalytic subunit, and a 110–133-kDa myosin-targeting subunit (MYPT1). Alternative mRNA splicing produces four MYPT1 isoforms, differing by the presence or absence of a central insert and leucine zipper (LZ). The LZ domain of MYPT1 has been shown to be important for PKGIα-mediated activation of MLC phosphatase activity, and changes in LZ+ MYPT1 isoform expression result in changes in the sensitivity of smooth muscle to NO-mediated relaxation. Furthermore, PKGIα has been demonstrated to phosphorylate Ser-694 of MYPT1, but phosphorylation at this site does not always accompany cGMP-mediated smooth muscle relaxation. This study was designed to determine whether MYPT1 isoforms are differentially phosphorylated by PKGIα. The results demonstrate that purified LZ+ MYPT1 fragments are rapidly phosphorylated by PKGIα at Ser-667 and Ser-694, whereas fragments lacking the LZ domain are poor PKGIα substrates. Mutation of Ser-667 and Ser-694 to Ala and/or Asp showed that Ser-667 phosphorylation is more rapid than Ser-694 phosphorylation, suggesting that Ser-667 may play an important role in the activation of MLC phosphatase. These results demonstrate that MYPT1 isoform expression is important for determining the heterogeneous response of vascular beds to NO and NO-based vasodilators, thereby playing a central role in the regulation of vascular tone in health and disease.

1 September 2018 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
MLMelissa A. Lyle
Melissa A. Lyle
FBFrank V. Brozovich
Frank V. Brozovich

1 July 2009 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
SYSamantha L. Yuen
Samantha L. Yuen
OOOzgur Ogut
Ozgur Ogut
FBFrank V. Brozovich
Frank V. Brozovich
The participation of nonmuscle myosin in force maintenance is controversial. Furthermore, its regulation is difficult to examine in a cellular context, as the light chains of smooth muscle and nonmuscle myosin comigrate under native and denaturing electrophoresis techniques. Therefore, the regulatory light chains of smooth muscle myosin (SM-RLC) and nonmuscle myosin (NM-RLC) were purified, and these proteins were resolved by isoelectric focusing. Using this method, intact mouse aortic smooth muscle homogenates demonstrated four distinct RLC isoelectric variants. These spots were identified as phosphorylated NM-RLC (most acidic), nonphosphorylated NM-RLC, phosphorylated SM-RLC, and nonphosphorylated SM-RLC (most basic). During smooth muscle activation, NM-RLC phosphorylation increased. During depolarization, the increase in NM-RLC phosphorylation was unaffected by inhibition of either Rho kinase or PKC. However, inhibition of Rho kinase blocked the angiotensin II-induced increase in NM-RLC phosphorylation. Additionally, force for angiotensin II stimulation of aortic smooth muscle from heterozygous nonmuscle myosin IIB knockout mice was significantly less than that of wild-type littermates, suggesting that, in smooth muscle, activation of nonmuscle myosin is important for force maintenance. The data also demonstrate that, in smooth muscle, the activation of nonmuscle myosin is regulated by Ca2+-calmodulin-activated myosin light chain kinase during depolarization and a Rho kinase-dependent pathway during agonist stimulation.

1 July 2020 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
JBJ. Martijn Bos
J. Martijn Bos
VHVirginia B. Hebl
Virginia B. Hebl
AOAnn L. Oberg
Ann L. Oberg
ZSZhifu Sun
Zhifu Sun
DHDaniel S. Herman
Daniel S. Herman
MAMichael J. Ackerman
Michael J. Ackerman

1 November 2014 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
SYSamantha L. Yuen
Samantha L. Yuen
OOOzgur Ogut
Ozgur Ogut
FBFrank V. Brozovich
Frank V. Brozovich

23 August 2017 in Frontiers in Physiology
Verified
Journal Article
Open access
MLMelissa A. Lyle
Melissa A. Lyle
JDJonathan P. Davis
Jonathan P. Davis
FBFrank V. Brozovich
Frank V. Brozovich
There are two primary components that produce PAH; aberrant structural changes (smooth muscle cell proliferation, smooth muscle cell hypertrophy and the deposition of matrix proteins within the media of pulmonary arterial vessels), and excess vasoconstriction. However, in PAH, the target and aim of all current therapeutic agents is to reduce the contractility of the pulmonary vasculature; prostaglandins, phosphodiesterase inhibitors, guanylate cyclase stimulators, endothelin antagonists, NO inhalation & Rho kinase inhibitors all influence signaling pathways in the pulmonary vascular smooth muscle to decrease vasoconstriction, and hence, pulmonary vascular resistance. This review will therefore primarily focus on discussing the signaling pathways regulating contractility in pulmonary vascular smooth muscle, the mechanism for current treatments, as well as highlighting potential targets for the development of novel therapies.